ROCKVILLE, Md., March 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has promoted Mark R. Bray, Ph.D. to Vice President, Research and Anthony M. Treston, Ph.D. to Vice President, Product Development and Manufacturing.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
As Vice President, Research, Dr. Bray will manage EntreMed’s Toronto R&D site; coordinate research activities between Rockville and Toronto; and manage the kinase inhibitor program, HDAC inhibitor program, and preclinical support for the MKC-1 program. Dr. Bray will lead the Company’s efforts to identify new areas of research, including new compounds, targets and collaborations. He will also work closely with Corporate Development to identify strategic business opportunities, such as new technology, products and companies, and will coordinate EntreMed’s internal and external scientific due diligence of these opportunities. He was most recently Senior Director, Preclinical Sciences. Dr. Bray joined the EntreMed team in January 2006 through the acquisition of Miikana Therapeutics and is based in Toronto.
As Vice President, Product Development and Manufacturing, Dr. Treston will manage all EntreMed activities associated with drug product and process development, including formulation, drug delivery, technology transfer, and scale-up. Dr. Treston will also have responsibility for manufacturing, including drug substance (API), drug product, and finish/fill for our clinical trials, commercial production, and IND-enabling studies. Dr. Treston will be responsible for identifying, evaluating and qualifying global contract manufacturing organizations (CMOs) for raw materials, intermediates and finished products. He was most recently Senior Director, Medicinal and Analytical Chemistry. Dr. Treston joined EntreMed in 1998 and is based in Rockville.
James S. Burns, EntreMed President and Chief Executive Officer, commented on the announcement, “The promotions of Drs. Bray and Treston reflect well upon the caliber of our R&D team and the progress we are making with our pipeline. At this stage, we need to both drive our promising research programs and enhance our capabilities in formulation development and manufacturing behind our lead clinical programs.”
Mr. Burns further commented, “We have made significant progress in building an oncology business based on multiple oncology drugs with convenient oral formulations that work through multiple mechanisms of action. We currently have 12 clinical oncology trials underway with three product candidates, and we are working toward filing two additional INDs this year. The new management appointments will help ensure that we continue to execute on our commitments to patients and to our shareholders.”
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn Associate Director, Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comEntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com/
